CHRO_OUT_1 [2025-04-17 09:31:47 -0400] 4164 Bytes | 1084 tokens | Cum: 1084 tkns (13.55% of 8k)
==========================================================================

Alright, let’s light it up, because it's 9:31:45 AM on Thu Apr 17, 2025 -0400, and I'm charging into Channel Therapeutics (CHRO), popping from 1.2550 to 2.1850. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Channel Therapeutics (CHRO)
IPO: 2024-02-16 (1 Year Ago)
Market Cap: $7,565,154
Shares Outstanding: 6,100,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XASE
Description: Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Here’s a list of headlines for Channel Therapeutics:

Today 06:00AM - Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
05:45AM - EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity
Apr-04-25 09:35AM - Roches Genentech present data on trontinemab, Elecsys plasma test
Dec-20-24 09:00AM - Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
Dec-18-24 08:30AM - Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
Nov-21-24 09:49AM - Chromocell Announces Name Change to "Channel Therapeutics Corporation" and Provides Therapeutic Program Updates
Oct-29-24 08:30AM - Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain
Oct-28-24 08:00AM - Chromocell to Present at Upcoming Fall Investor Conferences

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-17T10:00:00Z - Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
B2 - 2024-05-13T13:00:00Z - Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024
B3 - 2024-04-17T17:36:19Z - Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B4 - 2024-04-17T10:13:57Z - Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket
B5 - 2024-04-09T12:30:00Z - Chromocell Issues Letter to Stockholders from Chief Executive Officer
B6 - 2024-02-21T21:47:00Z - Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Channel Therapeutics (CHRO).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

CHRO_OUT_3 [2025-04-17 09:31:47 -0400] 850 Bytes | 225 tokens | Cum: 1311 tkns (16.39% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/17/3063185/0/en/Ligand-Subsidiary-Pelthos-Therapeutics-to-Combine-with-Channel-Therapeutics.htmlLigand Pharmaceuticals and Channel Therapeutics announced a merger agreement, where Ligand's Pelthos Therapeutics subsidiary will be combined with Channel. The combined company will focus on commercializing Pelthos' FDA-approved ZELSUVMI for the treatment of Molluscum contagiosum infections.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CHRO_OUT_5 [2025-04-17 09:31:48 -0400] 942 Bytes | 285 tokens | Cum: 1598 tkns (19.98% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-17T12:09:34Z - 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Forian (NASDAQ:FORA), Channel Therap...
A2 - 2025-04-17T11:47:16Z - Ligand, Channel Agree To Combine Pelthos, LNHC With CHRO Merger Sub...
A3 - 2025-04-17T11:14:00Z - Ligand Pharmaceuticals and Channel Therapeutics Announce $50 Million Merger to Advance ZELSUVMI™ for...
A4 - 2025-04-17T11:00:00Z - Ligand, Channel Agree To Combine Pelthos, LNHC With CHRO Merger Sub...
A5 - 2025-04-17T11:18:00Z - Ligand, Channel Agree To Combine Pelthos, LNHC With CHRO Merger Sub...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CHRO_OUT_7 [2025-04-17 09:31:50 -0400] 1181 Bytes | 348 tokens | Cum: 1948 tkns (24.35% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Thursday's Pre-Market Session - Forian (NASDAQ:FORA), Channel Therapeutics (AMEX:CHRO)**Date: 2025-04-17Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44861498/12-health-care-stocks-moving-in-thursdays-pre-market-sessionGainers Channel Therapeutics CHRO stock increased by 86.5% to $2.34 during Thursday's pre-market session. The market value of their outstanding shares is at $14.1 million. Sharps Technology STSS stock rose 34.33% to $0.04. InnovAge Holding INNV stock increased by 19.71% to $3.4. The market value of their outstanding shares is at $459.8 million. Quoin Pharmaceuticals QNRX stock increased by 19.35% to $7.16. The market value of their outstanding shares is at $147.4 million. Sunshine Biopharma SBFM shares rose 14.75% to $1.4. The market value of their outstandin

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CHRO_OUT_9 [2025-04-17 09:31:51 -0400] 1181 Bytes | 345 tokens | Cum: 2295 tkns (28.69% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): g shares is at $5.0 million. China SXT Pharmaceuticals SXTC shares rose 14.25% to $1.13. The company's market cap stands at $15.5 million. Losers Forian FORA shares fell 36.0% to $1.26 during Thursday's pre-market session. The market value of their outstanding shares is at $39.3 million. TNF Pharmaceuticals TNFA shares decreased by 23.9% to $0.19. As per the news, the Q4 earnings report came out 4 days ago. Sophia Genetics SOPH stock declined by 19.58% to $2.26. The company's market cap stands at $150.1 million. UnitedHealth Group UNH stock declined by 19.33% to $472.0. The company's market cap stands at $431.7 billion. As per the press release, Q1 earnings came out today. Tourmaline Bio TRML shares declined by 15.98% to $12.2. The company's market cap stands at $313.3 million. enVVeno Medical NVNO shares declined by 15.13% to $2.02. The company's market cap stands at $35.4 million. See

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CHRO_OUT_11 [2025-04-17 09:31:52 -0400] 1097 Bytes | 353 tokens | Cum: 2650 tkns (33.12% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHROChannel Therapeutics Corp$2.3788.8%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum73.30Price TrendShortMediumLongOverviewFORAForian Inc$1.25-36.5%INNVInnovAge Holding Corp$3.2012.7%NVNOenVVeno Medical Corp$2.02-15.1%QNRXQuoin Pharmaceuticals Ltd$6.6811.3%SBFMSunshine Biopharma Inc$1.230.82%SOPHSophia Genetics SA$2.25-19.9%STSSSharps Technology Inc$0.036537.7%SXTCChina SXT Pharmaceuticals Inc$1.1011.2%TNFATNF Pharmaceuticals Inc$0.1936-21.2%TRMLTourmaline Bio Inc$12.20-16.0%UNHUnitedHealth Group Inc$473.00-19.1%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CHRO_OUT_13 [2025-04-17 09:31:53 -0400] 1107 Bytes | 286 tokens | Cum: 2938 tkns (36.73% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-17 8-K Item 1.01. Entry into a Material Definitive Agrmt

Merger Agrmt

On April 16, 2025, Channel Therapeutics Corporation, a Nevada corporation ( Channel ), CHRO Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Channel (the Merger Sub ), and LNHC, Inc.,...

S4 - 2025-03-27 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and related notes appear...

S5 - 2025-03-03 8-K Item 1.01 Entry into a Material Definitive Agrmt

On February 25, 2025, Channel Therapeutics Corporation (the Company) issued an unsecured promissory note in the aggregate principal amount of $325,000 (the Note) to 3i, L.P., a Delaware limited partnership (the Holder), for a...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CHRO_OUT_15 [2025-04-17 09:31:53 -0400] 1181 Bytes | 277 tokens | Cum: 3217 tkns (40.21% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 1.01. Entry into a Material Definitive Agreement

Merger Agreement

On April 16, 2025, Channel Therapeutics Corporation, a Nevada corporation ( Channel ), CHRO Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Channel (the Merger Sub ), and LNHC, Inc., a Delaware corporation ( LNHC ), and solely for the purposes of Article III thereof, Ligand Pharmaceuticals Incorporated, a Delaware corporation and the parent of LNHC ( Ligand ) entered into an Agreement and Plan of Merger (the Merger Agreement ), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into LNHC, with LNHC continuing as a wholly-owned subsidiary of Channel and the surviving corporation of the merger (the Merger ). The Merger is intended to qualify for federal income tax purposes as

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CHRO_OUT_17 [2025-04-17 09:31:55 -0400] 1181 Bytes | 285 tokens | Cum: 3504 tkns (43.80% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): a tax-free reorganization under the provisions of Section 368(a) of the Internal Revenue Code of 1986, as amended (the Code ), or, in the event that the former stockholders of LNHC and certain other persons are in control of Channel immediately after the Merger (within the meaning of Section 368(c) of the Code), the Merger is also intended to qualify as a non-taxable exchange of shares of LNHC capital stock for Channel common stock, par value $0.0001 per share (the Common Stock ), within the meaning of Section 351(a) of the Code.

Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the Effective Time ), each then outstanding share of LNHC capital stock will be converted into the right to receive a number of shares of Series A Convertible Preferred Stock, par value $0.0001 per share (the Series A Preferred Stock ) of Channel (subject to the pa

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CHRO_OUT_19 [2025-04-17 09:31:57 -0400] 1181 Bytes | 261 tokens | Cum: 3767 tkns (47.09% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): yment of cash in lieu of fractional shares) calculated in accordance with the Merger Agreement (the ratio of such conversion, the Exchange Ratio ). The Exchange Ratio represents the number of shares of Common Stock issuable upon conversion of the Series A Preferred Stock that will be received for each LNHC share outstanding immediately prior to the Merger. It is calculated by dividing the shares of Common Stock (derived from the post-closing shares of Common Stock and the LNHC allocation percentage based on the relative valuations of $67 million for LNHC and $15 million for Channel) by the total number of LNHC shares outstanding.

Based on current capitalization, upon the closing of the Merger, after giving effect to the PIPE Financing (as defined below), on a pro forma basis and based upon the number of shares of Common Stock expected to be issued in the Merger, Channel securityholders

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CHRO_OUT_21 [2025-04-17 09:31:58 -0400] 1181 Bytes | 266 tokens | Cum: 4035 tkns (50.44% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): as of immediately prior to the Merger are expected to own approximately 7.7% of the outstanding shares of capital stock of Channel, Ligand, including its participation in the PIPE Financing, is expected to own approximately 55.1% of the outstanding shares of capital stock of Channel, and the other PIPE Investors (as defined below) are expected to own approximately 37.2% of the outstanding shares of capital stock of Channel, in each case, on a fully-diluted basis, calculated using the treasury stock method, subject to certain assumptions, including, but not limited to, a valuation for LNHC equal to $67 million and a valuation for Channel equal to $15 million, in each case as further described in the Merger Agreement. For purposes of calculating the Exchange Ratio, shares of Common Stock underlying Channel stock options outstanding as of immediately prior to the closing of the Merger with

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CHRO_OUT_23 [2025-04-17 09:31:59 -0400] 1181 Bytes | 255 tokens | Cum: 4292 tkns (53.65% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): an exercise price of less than the volume weighted average closing trading price of a share of Common Stock on The NYSE American LLC (the NYSE American ) for the five consecutive trading days ending five trading days immediately prior to the closing of the Merger will be deemed to be outstanding, and, such shares will be calculated using the treasury stock method.

Each of Channel and LNHC has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (i) obtaining the requisite approvals of their respective stockholders, (ii) non-solicitation of alternative acquisition proposals, (iii) the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger and (iv) Channel using its commercially reasonable efforts to maintain the existing listing

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CHRO_OUT_25 [2025-04-17 09:31:59 -0400] 790 Bytes | 188 tokens | Cum: 4482 tkns (56.03% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): of the Common Stock on the NYSE American and Channel causing the shares of Common Stock issuable upon conversion of the Series A Preferred Stock to be issued in connection with the Merger to be approved for listing on the NYSE American at or prior to the Effective Time.

The consummation of the Merger is subject to certain closing conditions, including, among other things, (i) the Merger Agreement having been approved by means of written consents by the requisite stockholders of LNHC and Channel, (...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

CHRO_OUT_27 [2025-04-17 09:32:07 -0400] 6043 Bytes | 1589 tokens | Cum: 6073 tkns (75.91% of 8k)
==========================================================================

This is our set of metrics for Channel Therapeutics.
Please analyze the numbers.

+---------------------+----------------------+-----------------------+-------------------+
| Volume: 0 | Perf Month: -20.57% | Option/Short: No / No | Sales Y/Y TTM: - |
+---------------------+----------------------+-----------------------+-------------------+
| Avg Volume: 817.87K | Perf Quarter: 28.98% | Short Float: 0.95% | ROE: - |
+---------------------+----------------------+-----------------------+-------------------+
| Rel Volume: 0.00 | Index: - | Short Ratio: 0.01 | ROI: - |
+---------------------+----------------------+-----------------------+-------------------+
| RSI (14): 38.63 | Market Cap: 7.66M | Short Interest: 0.01M | Sales Surprise: - |
+---------------------+----------------------+-----------------------+-------------------+
| ATR (14): 0.16 | Shs Outstand: 5.82M | Beta: 4.04 | EPS Surprise: - |
+---------------------+----------------------+-----------------------+-------------------+
| SMA20: -10.69% | Shs Float: 1.24M | Sales Q/Q: - | P/E: - |
+---------------------+----------------------+-----------------------+-------------------+
| SMA50: -23.39% | Inst Own: 8.22% | Sales past 5Y: - | Earnings: - |
+---------------------+----------------------+-----------------------+-------------------+
| SMA200: 12.69% | Insider Own: 79.64% | Employees: - | |
+---------------------+----------------------+-----------------------+-------------------+
| Perf Week: -9.71% | Insider Trans: 0.00% | Debt/Eq: - | |
+---------------------+----------------------+-----------------------+-------------------+

The next section covers any insider trading by Channel Therapeutics officers or majority shareholders (if available).

Inside Trans: Channel Therapeutics Corp (CHRO) by Francis Knuettel II (CEO, Pres., CFO, Treas & Secty) on 2025-04-11
- Stock Option: 53988 shares at $N/A (D)

Inside Trans: Channel Therapeutics Corp (CHRO) by Simmons Chia-Lin (Unknown Title) on 2025-04-11
- Stock Option: 25000 shares at $N/A (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -7955338.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.2306
Average Volume: 913996.09
30-Day High: 2.2306
30-Day Low: 1.255

[Detailed Financials: TTM 2024]
- Total Assets: $1,369,143.0
- Total Liabilities: $4,083,197.0
- Total Equity: $-2,714,054.0
- Current Assets: $1,369,143.0
- Current Liabilities: $4,083,197.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.43

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $0

[Detailed Financials: FY 2024]
- Total Assets: $1,369,143.0
- Total Liabilities: $4,083,197.0
- Total Equity: $-2,714,054.0
- Current Assets: $1,369,143.0
- Current Liabilities: $4,083,197.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.43

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Channel Therapeutics (CHRO).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Channel Therapeutics.

2) MARKET_SCORE[]
This conversation was initiated because CHRO is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for CHRO.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, CHRO could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect CHRO to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Channel Therapeutics.

11) ETHICAL_RATING[]
Rate Channel Therapeutics’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Channel Therapeutics.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

CHRO_IN_29 [2025-04-17 09:32:07 -0400] 126 Bytes | 29 tokens | Cum: 6291 tkns (78.64% of 8k)
==========================================================================

====================================
[2025-04-17 09:32:07] # Analysis Completed
Elapsed Time: 21.53 seconds